Therefore, it may be valuable to evaluate clinically RAC1 mutational signature as a predictive biomarker for MEK/RAF inhibitor and anti-PD-1 and PD-L1 therapy resistance in melanoma patients. This evidence concerns the gene RAC1 and melanoma.